^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    GuardantOMNI

    Company:
    Guardant Health
    Type:
    Laboratory Developed Test
    Related tests:
    GuardantOmni is a comprehensive genomic profiling tool to help accelerate clinical development programs in immuno-oncology and targeted therapy. A 500-gene panel with comparable performance incorporating the vast majority of all genes being evaluated in cancer drug development pipelines and biomarkers for immuno-oncology applications, including tumor mutational burden.
    Cancer:
    Colorectal Cancer, Non Small Cell Lung Cancer
    Gene:
    MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Circulating Tumor DNA (ctDNA)
    Confirmatory trial(s)
    MYSTIC
    ,
    NCT02453282
    |
    Clin Cancer Res